Hostname: page-component-848d4c4894-pftt2 Total loading time: 0 Render date: 2024-06-05T06:05:20.727Z Has data issue: false hasContentIssue false
  • English
  • Français

Antinuclear autoantibodies in relation to bipolar affective disorder and lithium therapy

Published online by Cambridge University Press:  16 April 2020

B Spivak ,
M Radwan ,
P Bartur ,
R Mester  and
A Weizman
B Spivak
Affiliation:
Research Unit, Ness Ziona Psychiatric Hospital, Ness Ziona
M Radwan
Affiliation:
Geha Psychiatric Hospital, Beilinson Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv
P Bartur
Affiliation:
Laboratory of Clinical Immunology, Zamenhoff Laboratory Center, Tel Aviv
R Mester
Affiliation:
Research Unit, Ness Ziona Psychiatric Hospital, Ness Ziona
A Weizman
Affiliation:
Laboratory of Biological Psychiatry, Felsenstein Medical Research Center, Beilinson Medical Center, and Research Unit, Geha Psychiatric Hospital, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
Get access

Summary

We investigated the presence of antinuclear antibodies (ANA) in 63 drug free and lithium treated bipolar patients as compared to 37 healthy controls. Increased frequency of positive ANA was detected in bipolar patients in comparison to controls (19% vs 5%, respectively, P < 0.05). This finding was unrelated to lithium treatment. No antinative DNA antibodies or antihistone reactive antibodies were detected among the ANA positive subjects.

Keywords

bipolar affective disorderlithiumantinuclear antibodies (ANA)autoimmunity
Type
Short communication
Information
European Psychiatry , Volume 11 , Issue 1 , 1996 , pp. 50 - 52
Copyright
Copyright © 1996 Elsevier, Paris

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Aranth, JJohnson, RKataria, PVan de Water, SKamal, MMiller, MImmune dysfunction in psychiatric patients. Psych J Univ Ottawa 1989; 14: 542–546Google Scholar
Dorian, BGarfinkel, PStress, immunity and illness — a review. Psychol Med 1987; 17: 393–407CrossRefGoogle ScholarPubMed
Epstein, AGreenberg, MHalbert, SKramer, LBarland, PThe clinical application of an ELISA technique for the detection of antihistone antibodies. J Rheumatol 1983; 13: 304–307Google Scholar
Hart, DAZhao, PLen, ZSLithium treatment of MRL-Ipr mice alters disease progression in this murene model of systemic lupus erythematosus Lithium 4 1991 6168Google Scholar
Irwin, MCaldwell, CSmith, TLBrown, SSchuckit, MAGillin, JCMajor depressive disorder, alcoholism, and reduced natural killer cell cytotoxicity. Arch Gen Psychiatry 1990; 47: 713–718CrossRefGoogle ScholarPubMed
Jansen, EMPeng, JSBeutner, EHKumar, VChorzeski, TComparison of commercial kits for the detection of anti n-DNA antibodies using Crithidiae Iuciliae. Am J Clin Pathol 1987; 87: 461–469CrossRefGoogle Scholar
Johnstone, ECWhaley, KAntinucelar antibodies in psychiatric illness: their relationship to diagnosis and drag treatment Br Med J i 1975 724725CrossRefGoogle Scholar
Kronfel, ZSilva, JGreden, JDembinski, SGardner, RCarrol, BImpaired lyymphocyte function in depressive illness. Life Sci 1983; 33: 241–247CrossRefGoogle Scholar
Lazarus, LMKitron, NDepression of DNA-polimerase activity by lithium Lancet ii 1974 225226Google Scholar
Presley, APKahn, AWilliamson, NAntinuclear antibodies in patients on lithium carbonate Br Med J ii 1976 280281CrossRefGoogle Scholar
Prost, ACAbuaf, NRouquette-Gally, MHomberg, JCCombrisson, AComparing HEp-2 cell line with rat liver in routine screening test for antinuclear and antinucleolar autoantibodies in autoimmune diseases. Ann Biol Clin 1987; 45: 610–617Google ScholarPubMed
Schleifer, SJKeller, SEMeyerson, ATRaskin, MJDavis, KLStein, MLymphocyte function in major depressive disorder. Arch Gen Psychiatry 1984; 41: 484–486CrossRefGoogle ScholarPubMed
Solomon, GFAllansmith, MMcClellan, BAmkraut, AImmunoglobulins in psychiatric patients. Arch Gen Psychiatry 1969; 20: 272–277CrossRefGoogle ScholarPubMed
Spitzer, RLEdincott, JSchedule for affective disorders and schizophrenia — lifetime version 3rd ed New YorkNew York Psychiatric Institute 1979Google Scholar
Stein, MMiller, AHTrestman, RLDepression the immune system and health and illness. Arch Gen Psychiatry 1991; 48: 171–177CrossRefGoogle ScholarPubMed
Tan, EMAntinuclear antibodies in diagnosis and management. Hospital Practice 1983; 18: 79–84CrossRefGoogle ScholarPubMed
Villemain, FMagnin, MFeuillet-Fieux, MNZarifian, ELoo, HBach, JFAntihistone antibodies in schizophrenia and affective disorders. Psychiatry Res 1988; 24: 53–60CrossRefGoogle Scholar
Von Brauchitsch, HAntinuclear factor in psychiatric disorders. Am J Psychiatry 1972; 128: 1552–1554Google ScholarPubMed
Whalley, LJRoberts, DFWentzel, JWatson, KCAntinuclear antibodies and histocompatibility antigens in patients on long-term lithium therapy. J Affective Disord 1981; 3: 123–130CrossRefGoogle ScholarPubMed
Submit a response

Comments

No Comments have been published for this article.